Journal of Movement Disorders

Review Article

GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy: Young Eun Huh, Tatiana Usnich, Clemens R. Scherzer, Christine Klein, Sun Ju Chung; J Mov Disord. 2023;16(3):261-278. Published online June 12, 2023; DOI: https://doi.org/10.14802/jmd.23023

16,171 View
612 Download
26 Web of Science
27 Crossref

Glucosylceramidase beta 1 (GBA1) variants have attracted enormous attention as the most promising and important genetic candidates for precision medicine in Parkinson’s disease (PD). A substantial correlation between GBA1 genotypes and PD phenotypes could inform the prediction of disease progression and promote the development of a preventive intervention for individuals at a higher risk of a worse disease prognosis. Moreover, the GBA1-regulated pathway provides new perspectives on the pathogenesis of PD, such as dysregulated sphingolipid metabolism, impaired protein quality control, and disrupted endoplasmic reticulum-Golgi trafficking. These perspectives have led to the development of novel disease-modifying therapies for PD targeting the GBA1-regulated pathway by repositioning treatment strategies for Gaucher’s disease. This review summarizes the current hypotheses on a mechanistic link between GBA1 variants and PD and possible therapeutic options for modulating GBA1-regulated pathways in PD patients.

Citations

Citations to this article as recorded by

Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson’s disease
Mohit Kwatra, Gijung Kwak, Haolin Li, Jung Soo Suk, Han Seok Ko
Drug Delivery and Translational Research.2026; 16(3): 894. CrossRef
Selenoureido-N-alkyl-3,4,5-trihydroxypiperidines: probing their dual-target role in Gaucher disease
Debora Pratesi, Francesca Clemente, Camilla Matassini, Silvia Falliano, Amelia Morrone, Rebecca Sodano, Paolo Paoli, Andrea Goti, José G. Fernández-Bolanos, Óscar López, Francesca Cardona
Bioorganic & Medicinal Chemistry.2026; 132: 118453. CrossRef
Multi-cohort, cross-species urinary proteomics reveals signatures of LRRK2 dysfunction in Parkinson’s disease
Duc Tung Vu, William Sibran, Andreas Metousis, Laurine Vandewynckel, Basak Eraslan, Liesel Goveas, Ericka CM Itang, Claire Deldycke, Adriana Figueroa-Garcia, Réginald Lefèbvre, Johannes Bruno Müller-Reif, Sebastian Virreira Winter, Marie-Christine Chartie
Molecular Systems Biology.2026;[Epub] CrossRef
Benchmarking Lysosome Enrichment Methods: A Guide for Research and Clinical Translation
Anniek L. de Jager, Sara Kassem, Louis Alesha, Brigitta A.E. Naber, Inge F. de Laat, Bas de Mooij, Kyra van der Pan, Erik Bos, Roman I. Koning, Jacques J.M. van Dongen, Cristina Teodosio, Paula Díez
Analytical Chemistry.2026; 98(6): 4585. CrossRef
Lysosome pH Dynamics in Physiology and Disease: Molecular Mechanisms and Therapeutic Insights
Sonia Infante‐Tadeo, Diane L. Barber
Acta Physiologica.2026;[Epub] CrossRef
Male sex accelerates cognitive decline in GBA1 Parkinson’s disease
Silvia Paola Caminiti, Micol Avenali, Alice Galli, Rachele Malito, Giada Cuconato, Caterina Galandra, Rosaria Calabrese, Andrea Pilotto, Alessandro Padovani, Fabio Blandini, Daniela Perani, Cristina Tassorelli, Enza Maria Valente
npj Parkinson's Disease.2025;[Epub] CrossRef
Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review
Malco Rossi, Susen Schaake, Tatiana Usnich, Josephine Boehm, Nina Steffen, Nathalie Schell, Clara Krüger, Tuğçe Gül‐Demirkale, Natascha Bahr, Teresa Kleinz, Harutyun Madoev, Björn‐Hergen Laabs, Ziv Gan‐Or, Roy N. Alcalay, Katja Lohmann, Christine Klein
Movement Disorders.2025; 40(4): 605. CrossRef
Challenges in Gaucher disease: Perspectives from an expert panel
Gregory A. Grabowski, Priya S. Kishnani, Roy N. Alcalay, S. Grace Prakalapakorn, Barry E. Rosenbloom, Dominick A. Tuason, Neal J. Weinreb
Molecular Genetics and Metabolism.2025; 145(1): 109074. CrossRef
Acetal functionalized iminosugars for targeting β-glucocerebrosidase modulation
Maria Giulia Davighi, Francesca Clemente, Camilla Matassini, Martina Cacciarini, Damiano Tanini, Andrea Goti, Amelia Morrone, Paolo Paoli, Francesca Cardona
European Journal of Medicinal Chemistry.2025; 290: 117529. CrossRef
Comparative analysis of methods for measuring glucocerebrosidase enzyme activity in patients with Parkinson’s disease with the GBA1 variant
Jin Hwangbo, Myung Jun Lee, Sang Jin Kim, Hyun Kyung Park, Jae-Hyeok Lee
Frontiers in Neurology.2025;[Epub] CrossRef
A drug screening platform for protein expression levels in neurological disorders
Farida Emran, Ibrahim Kays, Chiu-An Lo, Yueyang Li, Brian E. Chen
BioTechniques.2025; 77(3): 113. CrossRef
Investigating plasma lipid profiles in association with Parkinson’s disease risk
Houwen Zhang, Fangzheng Cao, Jialin Yu, Yu Liang, You Wu
npj Parkinson's Disease.2025;[Epub] CrossRef
Efficient GBA1 editing via HDR with ssODNs by outcompeting pseudogene-mediated gene conversion upon CRISPR/Cas9 cleavage
Joseph S. Lagas, Monica F. Sentmanat, Xiaoxia Cui
Frontiers in Genome Editing.2025;[Epub] CrossRef
Adaptive immunity in the pathogenesis and treatments of Parkinson’s disease
Xiaoqing Du, Samia Akter, Davina B. Oludipe, Susmita Sil, Chen Zhang, Howard E. Gendelman, R. Lee Mosley
NeuroImmune Pharmacology and Therapeutics.2025; 4(2): 273. CrossRef
Protective Effects of Genetic Proxies of Cognitive Reserve in Parkinson's Disease: A Longitudinal Multi‐Cohort Study
Young Eun Huh, Beomjin Jang, Sang‐Hyuk Jung, Dokyoon Kim, Towfique Raj, Hong‐Hee Won
Movement Disorders.2025; 40(10): 2158. CrossRef
Intrathecal Therapies for Neurodegenerative Diseases: A Review of Current Approaches and the Urgent Need for Advanced Delivery Systems
Thomas Gabriel Schreiner, Manuel Menéndez-González, Oliver Daniel Schreiner, Romeo Cristian Ciobanu
Biomedicines.2025; 13(9): 2167. CrossRef
Clinical Variability and Genotype–Phenotype Correlation in Spanish Patients with Type 1 Gaucher Disease: A Focus on Non-c.[1226A>G]; [1448T>C] Genotypes
Irene Serrano-Gonzalo, Francisco Bauza, Laura Lopez de Frutos, Isidro Arevalo-Vargas, Mercedes Roca-Espiau, Marcio Andrade-Campos, Esther Valero-Tena, Sonia Roca-Esteve, David Iniguez, Pilar Giraldo
International Journal of Molecular Sciences.2025; 26(20): 10088. CrossRef
Secondary Mitochondrial Dysfunction in Gaucher Disease Type I, II and III—Review of the Experimental and Clinical Evidence
Mollie Dewsbury, Tyler Purcell, Derralynn Hughes, Aimee Donald, Iain P. Hargreaves, Karolina M. Stepien
Genes.2025; 16(11): 1269. CrossRef
Inhibition or genetic reduction of ASAH1/acid ceramidase restore α-synuclein clearance in mutant GBA1 dopamine neurons from Parkinson’s patients
Manoj Kumar, Ricardo A Feldman
Human Molecular Genetics.2025; 34(24): 2075. CrossRef
GBA1 Variants with Unknown Classification Are Modest Contributors to Parkinson's Disease Susceptibility
Sitki Cem Parlar, Yoomin Lee, Ziv Gan‐Or
Movement Disorders.2025;[Epub] CrossRef
A novel peptide-based strategy to enhance GBA1 expression for treating Parkinson’s disease
Hyerynn Kim, Jiyeon Na, Hye Guk Ryu, Eunmin Lee, Hyeonwoo Park, Haeun Park, Younwoo Nam, Geon-Hwi Jeong, In-Hyeok Pyo, Jung-Hyun Choi, Jihoon Nah, Sang-Min Jang, Jun-Ho Song, Sung-Jin Cho, Sangjune Kim
npj Parkinson's Disease.2025;[Epub] CrossRef
Racial and Ethnic Diversity in Clinical Trials for Disease Modifying Drugs in Parkinson Disease: A Systematic Review & Meta‐Analysis
Farley Reis Rodrigues, Gabriel Bolner, Giovana Barros e Silva Ribeiro, Aishwarya Koppanatham, Raul Vinícius da Silva, Conor Fearon, Artur F. Schumacher Schuh, Ece Bayram, Juan Blas M. Couto, Mwiza Ushe, Daniel G. Di Luca
Movement Disorders Clinical Practice.2025;[Epub] CrossRef
A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease
Makaila L. Furderer, Bahafta Berhe, Tiffany C. Chen, Stephen Wincovitch, Xuntian Jiang, Nahid Tayebi, Ellen Sidransky, Tae-Un Han
International Journal of Molecular Sciences.2024; 25(3): 1827. CrossRef
Towards a Global View of Parkinson's Disease Genetics
Marzieh Khani, Catalina Cerquera‐Cleves, Mariam Kekenadze, Peter Wild Crea, Andrew B. Singleton, Sara Bandres‐Ciga
Annals of Neurology.2024; 95(5): 831. CrossRef
Exploring the Association between Cathepsin B and Parkinson’s Disease
Changhao Lu, Xinyi Cai, Shilin Zhi, Xiaofen Wen, Jiaxin Shen, Tommaso Ercoli, Elena Rita Simula, Carla Masala, Leonardo A. Sechi, Paolo Solla
Brain Sciences.2024; 14(5): 482. CrossRef
Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
Xuxiang Zhang, Heng Wu, Beisha Tang, Jifeng Guo
Translational Neurodegeneration.2024;[Epub] CrossRef
Microglia: roles and genetic risk in Parkinson’s disease
Alex R. Trainor, Debra S. MacDonald, Jay Penney
Frontiers in Neuroscience.2024;[Epub] CrossRef

Case Report

A KMT2B Frameshift Variant Causing Focal Dystonia Restricted to the Oromandibular Region After Long-Term Follow-up: Alfand Marl F. Dy Closas, Katja Lohmann, Ai Huey Tan, Norlinah Mohamed Ibrahim, Jia Lun Lim, Yi Wen Tay, Kalai Arasu Muthusamy, Azlina Binti Ahmad-Annuar, Christine Klein, Shen-Yang Lim; J Mov Disord. 2023;16(1):91-94. Published online December 20, 2022; DOI: https://doi.org/10.14802/jmd.22109

4,107 View
110 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material

KMT2B-linked dystonia (DYT-KMT2B) is a childhood-onset dystonia syndrome typically beginning in the lower limbs and progressing caudocranially to affect the upper limbs with eventual prominent craniocervical involvement. Despite its recent recognition, it now appears to be one of the more common monogenic causes of dystonia syndromes. Here, we present an atypical case of DYT-KMT2B with oromandibular dystonia as the presenting feature, which remained restricted to this region three decades after symptom onset. This appears to be the first reported case of DYT-KMT2B from Southeast Asia and provides further supporting evidence for the pathogenic impact of the KMT2B c.6210_6213delTGAG variant.

Citations

Citations to this article as recorded by

New insights from a Malaysian real-world deep brain stimulation cohort
Alfand Marl F. Dy Closas, Ai Huey Tan, Yi Wen Tay, Jia Wei Hor, Tzi Shin Toh, Jia Lun Lim, Choey Yee Lew, Chun Yoong Cham, Carolyn Chue Wai Yim, Kok Yoon Chee, Chong Guan Ng, Lei Cheng Lit, Anis Nadhirah Khairul Anuar, Lara M. Lange, Zih-Hua Fang, Sara Ba
Journal of Parkinson’s Disease.2025; 15(1): 189. CrossRef
The Spectrum of Abnormal Tongue Movements: Review of Phenomenology, Etiology, and Differential Diagnosis
Nathaniel Bendahan, Seyed‐Mohammad Fereshtehnejad, Christos Ganos, Emily Swinkin, Anthony E. Lang
Movement Disorders Clinical Practice.2025;[Epub] CrossRef
Genetic Update and Treatment for Dystonia
Jan Koptielow, Emilia Szyłak, Olga Szewczyk-Roszczenko, Piotr Roszczenko, Jan Kochanowicz, Alina Kułakowska, Monika Chorąży
International Journal of Molecular Sciences.2024; 25(7): 3571. CrossRef
KMT2B-Related Dystonia in Indian Patients With Literature Review and Emphasis on Asian Cohort
Debjyoti Dhar, Vikram V Holla, Riyanka Kumari, Neeharika Sriram, Jitender Saini, Ravi Yadav, Akhilesh Pandey, Nitish Kamble, Babylakshmi Muthusamy, Pramod Kumar Pal
Journal of Movement Disorders.2023; 16(3): 285. CrossRef

First
Prev
Page of 1
Next
Last

Search